Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
复制标题
DOI：
10.1200/jco.2004.08.029
复制
发表时间：
2004-11-01
影响因子：
45.3
通讯作者：
Howell, A
中科院分区：
文献类型：
--
作者：
Fallowfield, L;Cella, D;Howell, A
目的确定在前2年的treatment.Patients和Methods期间，参与Arimidex、他莫昔芬单独或联合（ATAC）辅助乳腺癌试验的妇女的生活质量（QoL），共有1,021名妇女参加了QoL子方案。所有患者均完成了初步治疗（手术+/-放疗+/-化疗），并接受了为期5年的阿那曲唑（n = 335）、坦诺昔芬（n = 347）或两者联合（n = 339）辅助治疗。患者在基线和3、6、12、18和24个月或直至疾病复发时完成癌症治疗功能评估-乳腺（FACT-B）加内分泌子量表（ES）。主要终点是FACT-B试验结局指数（TOI）。次要终点是ES总分。个别内分泌症状的分析也explored.Results问卷调查完成约85%的评估可供分析。在2年期间，所有组的总体生活质量均较基线改善。治疗组间TOI或ES评分无显著差异。所有组的内分泌症状在基线和3个月之间增加，此后稳定。与对照组相比，在副作用方面存在一些小的差异。仅接受他莫昔芬治疗的患者，仅接受阿那曲唑治疗的患者报告的冷汗和阴道分泌物显著减少，但阴道干燥疼痛、性交和性兴趣丧失的患者更多。结论阿那曲唑、他莫昔芬或联合治疗2年的患者总体生活质量影响相似，随着时间的推移逐渐改善。所有三组的内分泌相关症状最初恶化，并在2年内部分恢复。所经历的不同症状可能有助于做出有关治疗和支持性护理需求的决策。(C)2004年美国临床肿瘤学会
Purpose To determine the quality of life (QoL) of women participating in the Arimidex, Tamoxifen Alone, or in Combination (ATAC) Adjuvant Breast Cancer Trial during the first 2 years of treatment.Patients and Methods A total of 1,021 women were enrolled onto the QoL subprotocol. All had completed primary treatment (surgery +/- radiotherapy +/- chemotherapy) and were to receive 5 years of adjuvant treatment with anastrozole (n = 335), tannoxifen (n = 347), or a combination (n = 339) of both. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) plus endocrine subscale (ES) at baseline and 3, 6, 12, 18 and 24 months or until disease,, recurrence. The primary end point was the FACT-B Trial Outcome Index (TOI). The secondary end point was the ES total score. Analyses of individual endocrine symptoms were also explored.Results Questionnaire completion approximated 85% of assessments available for analysis. Overall QoL for all groups improved from baseline during the 2-year period There were. no significant differences in TOI or ES scores across treatment groups. Endocrine symptoms increased between baseline and 3 months for all groups and stabilized thereafter. There were some small differences in side effect profiles Compared with. patients receiving tamoxifen only, patients receiving anastrozole only reported significantly fewer cold sweats and vaginal discharge, yet more vaginal dryness painful, intercourse and loss of sexual interest,.Conclusion Two years of treatment with anastrozole, tamoxifen, or the combination had a similar overall QoL impact, showing gradual improvement over time. Endocrine-related symptoms for all three arms worsened initially and recovered partially during 2 years. The different symptoms experienced may assist in decision making about treatment and supportive care needs. (C) 2004 by American Society of Clinical Oncology